Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer.

[1]  Yong Li,et al.  Single-cell RNA-sequencing data reveals the genetic source of extracellular vesicles in esophageal squamous cell carcinoma. , 2023, Pharmacological research.

[2]  Yan Li,et al.  Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer , 2023, Cancer science.

[3]  N. Ajami,et al.  Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial , 2023, Nature Medicine.

[4]  Anubhab Mukherjee,et al.  Lung cancer immunotherapy: progress, pitfalls, and promises , 2023, Molecular Cancer.

[5]  Yueming Sun,et al.  UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3 , 2022, Oncogene.

[6]  Shugeng Gao,et al.  RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer , 2022, EBioMedicine.

[7]  F. Hirsch,et al.  Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer , 2022, Journal of experimental & clinical cancer research : CR.

[8]  D. de Ruysscher,et al.  Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Fanshuang Zhang,et al.  Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[11]  Shugeng Gao,et al.  Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study , 2022, EBioMedicine.

[12]  Y. Shyr,et al.  Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Shugeng Gao,et al.  Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma , 2021, Cancer Immunology, Immunotherapy.

[14]  L. Goldfinger,et al.  Platelets and extracellular vesicles and their cross-talk with cancer. , 2021, Blood.

[15]  I. Wistuba,et al.  PD-L1 as a biomarker of response to immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.

[16]  K. Shannon,et al.  Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma , 2021, Nature Medicine.

[17]  Yanmei Zhang,et al.  Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  V. D'Agostino,et al.  RNA packaging into extracellular vesicles: An orchestra of RNA‐binding proteins? , 2020, Journal of extracellular vesicles.

[19]  S. Mandrekar,et al.  Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Yi-long Wu,et al.  Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer , 2020, Journal for ImmunoTherapy of Cancer.

[21]  Z. Wang,et al.  Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma , 2019, Gut.

[22]  H. Groen,et al.  Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[23]  H. Yao,et al.  Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer , 2019, JAMA network open.

[24]  Jiong Wu,et al.  Extracellular Vesicles Long RNA Sequencing Reveals Abundant mRNA, circRNA, and lncRNA in Human Blood as Potential Biomarkers for Cancer Diagnosis. , 2019, Clinical chemistry.

[25]  A. Drilon,et al.  PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Ellis,et al.  Long non-coding RNA MALAT1 suppresses breast cancer metastasis , 2018, Nature Genetics.

[27]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[28]  V. Velculescu,et al.  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  K. Bloom,et al.  Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Yi-Ching Wang,et al.  Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression , 2017, Molecular Cancer.

[31]  Joshua M. Weiss,et al.  Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. , 2016, Cancer cell.

[32]  M. Kris,et al.  Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. , 2015, The Cochrane database of systematic reviews.

[33]  S. Maeda,et al.  Ribosomal protein S3 regulates GLI2-mediated osteosarcoma invasion. , 2015, Cancer letters.

[34]  R. Nieuwland,et al.  Single-step isolation of extracellular vesicles by size-exclusion chromatography , 2014, Journal of extracellular vesicles.

[35]  Jeffrey E. Lee,et al.  Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma , 2012, Annals of surgery.

[36]  Yang Liu,et al.  Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  Aled Clayton,et al.  Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.

[38]  D. Beer,et al.  Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.